An arsenic oxide in which arsenic and oxygen atoms are present in the ratio 2:3.
Chemical ID:
MESH:C006632
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin promotes the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; 3,4-dihydro-5-(4-(1-piperidinyl)butoxy)-1(2H)-isoquinolinone inhibits the reaction [[Arsenic Trioxide co-treated with phytosphingosine] results in increased activity of PARP1 protein]; 6-Aminonicotinamide inhibits the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; [Arsenic Trioxide co-treated with Bortezomib] results in increased degradation of PARP1 protein; [Arsenic Trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein; [Arsenic Trioxide co-treated with IL24 protein] results in decreased expression of PARP1; [Arsenic Trioxide co-treated with MIR15A co-treated with MIR16-1] results in increased cleavage of PARP1 protein; [Arsenic Trioxide co-treated with PD 173074] results in increased expression of PARP1 protein modified form; [Arsenic Trioxide co-treated with phytosphingosine] results in increased activity of PARP1 protein; [Arsenic Trioxide co-treated with phytosphingosine] results in increased cleavage of PARP1 protein; [Arsenic Trioxide co-treated with Plant Extracts] results in increased cleavage of PARP1 protein; [Arsenic Trioxide results in increased susceptibility to PD 173074] which results in increased expression of PARP1 protein modified form; [Dasatinib co-treated with Arsenic Trioxide] results in increased cleavage of PARP1 protein; [Genistein co-treated with Arsenic Trioxide] results in increased cleavage of PARP1 protein; [MARVELD1 protein results in decreased susceptibility to Arsenic Trioxide] which results in decreased cleavage of PARP1 protein; [monomethylarsonous acid co-treated with dimethylarsinous acid co-treated with Arsenic Trioxide] results in increased cleavage of PARP1 protein; [PD 173074 results in increased susceptibility to Arsenic Trioxide] which results in increased expression of PARP1 protein modified form; [pifithrin co-treated with Arsenic Trioxide] results in decreased expression of PARP1 protein; [pifithrin co-treated with Arsenic Trioxide] results in increased cleavage of PARP1 protein; [sulforaphane co-treated with Arsenic Trioxide] results in increased cleavage of PARP1 protein; [Sulindac co-treated with Arsenic Trioxide] results in increased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [[Arsenic Trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; Acetylcysteine inhibits the reaction [[Arsenic Trioxide co-treated with phytosphingosine] results in increased activity of PARP1 protein]; Acetylcysteine inhibits the reaction [[monomethylarsonous acid co-treated with dimethylarsinous acid co-treated with Arsenic Trioxide] results in increased cleavage of PARP1 protein]; Acetylcysteine inhibits the reaction [[sulforaphane co-treated with Arsenic Trioxide] results in increased cleavage of PARP1 protein]; Acetylcysteine inhibits the reaction [[Sulindac co-treated with Arsenic Trioxide] results in increased cleavage of PARP1 protein]; Acetylcysteine inhibits the reaction [Arsenic Trioxide promotes the reaction [Cisplatin results in increased cleavage of PARP1 protein]]; Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased expression of PARP1 protein]; Acetylcysteine inhibits the reaction [Cisplatin promotes the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]]; Arsenic Trioxide promotes the reaction [Chloroquine results in increased cleavage of PARP1 protein]; Arsenic Trioxide promotes the reaction [Cisplatin results in increased cleavage of PARP1 protein]; Arsenic Trioxide promotes the reaction [Curcumin results in increased expression of PARP1 protein modified form]; Arsenic Trioxide promotes the reaction [Dasatinib results in increased cleavage of PARP1 protein]; Arsenic Trioxide promotes the reaction [Matrines results in increased cleavage of PARP1 protein]; Arsenic Trioxide promotes the reaction [Zoledronic Acid results in increased cleavage of PARP1 protein]; Arsenic Trioxide results in increased cleavage of and results in increased activity of PARP1 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Arsenic Trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[monomethylarsonous acid co-treated with dimethylarsinous acid co-treated with Arsenic Trioxide] results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; Cisplatin promotes the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; Curcumin promotes the reaction [Arsenic Trioxide results in increased expression of PARP1 protein modified form]; Dasatinib promotes the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; Deoxyglucose inhibits the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; Dithiothreitol inhibits the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; GSTP1 mutant form promotes the reaction [[Arsenic Trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; HSF1 protein affects the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; KNK 437 promotes the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; MARVELD1 protein inhibits the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; Matrines promotes the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; MCL1 mutant form promotes the reaction [[Arsenic Trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; NCF2 mutant form inhibits the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; PRDX3 protein affects the reaction [Arsenic Trioxide results in increased cleavage of and results in increased activity of PARP1 protein]; pyrazolanthrone inhibits the reaction [[Arsenic Trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [[Sulindac co-treated with Arsenic Trioxide] results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; TGIF1 mutant form promotes the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; TGIF1 protein inhibits the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]
[Genistein co-treated with Arsenic Trioxide] results in increased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased activity of PARP1 protein]; Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; Arsenic Trioxide promotes the reaction [Drugs, Chinese Herbal results in increased cleavage of PARP1 protein]; Deoxyglucose promotes the reaction [Metformin inhibits the reaction [Arsenic Trioxide results in increased expression of PARP1 protein modified form]]; Glucose deficiency inhibits the reaction [Arsenic Trioxide results in increased expression of PARP1 protein modified form]; Metformin inhibits the reaction [Arsenic Trioxide results in increased expression of PARP1 protein modified form]; Rotenone inhibits the reaction [Arsenic Trioxide results in increased expression of PARP1 protein modified form]
Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; salvianolic acid A inhibits the reaction [Arsenic Trioxide results in increased expression of PARP1 protein]
